Blue Jet Healthcare Q2 FY27 Sales Hit Record ₹3,757 Million, PAT Up 97% YoY
Blue Jet Healthcare reported record quarterly sales of ₹3,757 million for Q2 FY27. PAT surged 97% YoY to ₹1,025 million, while EBITDA grew 116% YoY to ₹1,188 million. The company achieved its highest-ever quarterly sales, driven by strong performance in Pharma Intermediates & API and Contrast Media segments. An R&D center in Hyderabad is now operational.
The announcement details record financial performance with substantial year-on-year growth across key metrics like revenue, EBITDA, and PAT, alongside strategic operational updates, which are material events for investors and significantly impact the company's valuation and outlook.
The company reported record quarterly sales, significant year-on-year growth in revenue, EBITDA, and PAT, along with operational updates on its R&D facility, indicating strong positive performance and future potential.
Blue Jet Healthcare Limited has announced its financial results for the quarter and half-year ended September 30, 2026. The company reported its highest ever quarterly sales at ₹3,757 million (approximately ₹375.7 crore) in Q2 FY27, representing a significant year-on-year (YoY) increase of 127% compared to ₹1,655 million (approximately ₹165.5 crore) in Q2 FY26.
EBITDA for Q2 FY27 also saw a substantial rise of 116% YoY to ₹1,188 million (approximately ₹118.8 crore), with a healthy EBITDA margin of 31.6%. Profit After Tax (PAT) surged by 97% YoY to ₹1,025 million (approximately ₹102.5 crore) from ₹521 million (approximately ₹52.1 crore) in the same period last year. The PAT margin stood at 27.3% in Q2 FY27.
On a quarter-on-quarter (QoQ) basis, revenue from operations increased by 28% to ₹3,757 million from ₹2,931 million in Q1 FY27. EBITDA grew by 21% QoQ to ₹1,188 million, and PAT rose by 31% QoQ to ₹1,025 million.
The strong performance in Q2 FY27 was driven by robust growth in the Pharma Intermediates & API category, which saw a 322% YoY increase in sales, and the Contrast Media segment, which grew by 80% YoY. The company also highlighted the operational status of its R&D center in Hyderabad, with 40 resources onboarded. Furthermore, Blue Jet Healthcare has successfully delivered and validated a new Contrast Media Intermediate to an innovator and expects to commercialize Amino Acid Derivatives for Peptide Fragments in Q4 FY27.
For the half-year ended September 30, 2027 (H1 FY27), revenue from operations grew by 29% YoY to ₹6,689 million (approximately ₹668.9 crore) from ₹5,202 million (approximately ₹520.2 crore) in H1 FY26. EBITDA increased by 23% YoY to ₹2,168 million (approximately ₹216.8 crore), and PAT rose by 26% YoY to ₹1,808 million (approximately ₹180.8 crore). Other income for H1 FY27 increased by 27% to ₹414 million, primarily due to higher net foreign exchange gains.
What to do with a filing like this
Blue Jet Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Blue Jet Healthcare Limited. Read the original for the full detail.